Innovation Spotlight VerAvanti is advancing intravascular visualization with the Scanning Fiber Endoscope (SFE), offering forward-looking, high-resolution vessel imaging that can help clinicians identify pathology earlier and plan interventions with greater confidence across cardiovascular, neurovascular, and peripheral applications. This positions the company to target medical centers and vascular specialties seeking cutting-edge imaging capabilities.

Funding Momentum With a Series A of 31.5 million USD and total funding around 38 million USD, VerAvanti demonstrates recent investor confidence and capital availability to scale manufacturing, clinical trials, and sales outreach. This supports a sales approach that emphasizes production ramp readiness and post-sale service commitments.

Early-Stage Growth Revenue is in the low single-digit millions with a lean team (11-50 employees), indicating a growing organization that can partner with hospitals and distributors on pilot deployments, early-adopter programs, and co-development opportunities to accelerate market penetration.

Awarded Credibility Recognition as a finalist for Innovation of the Year at the GeekWire Awards signals strong credibility in the medical technology space, which can be leveraged in outreach to clinicians, procurement teams, and academic medical centers to differentiate from incumbents.

Strategic Fit Opportunities The SFE’s focus on forward-looking, high-resolution imaging aligns with cardiovascular, neurovascular, and peripheral pathways, presenting cross-segment expansion opportunities with hospitals, large integrated delivery networks, and specialty clinics seeking enhanced diagnostic and interventional imaging capabilities.